Introduction
Approximately 3% of persons worldwide are infected with hepatitis C virus (HCV) [ 1 ] . Current therapy consisting of pegylated interferon (PEG-IFN)-α and ribavirin (RBV) produces sustained virologic response (SVR) rates of approximately 50% overall, with no effective alternative treatment for nonresponders. Host factors including obesity, insulin resistance, hepatic fi brosis, and African American ethnicity as well as viral factors such as genotype 1 and high baseline viral load are associated with lower SVR rates. Mathematical modeling serves as an important tool in understanding why these host and viral factors lower SVR rates.
Patterns of HCV RNA Kinetics

HCV RNA kinetics before and during therapy
During chronic HCV infection, the level of serum HCV RNA does not vary signifi cantly (< 0.5 log) on time scales of weeks to months [ 2 ] . However, when patients chronically infected with HCV are treated with IFN or IFN plus ribavirin, HCV RNA generally declines after a 7-to 10-hour delay. The typical decline is biphasic and consists of a rapid fi rst phase lasting approximately 1 to 2 days, during which HCV RNA, on average, may fall 1 to 2 logs in genotype 1-infected patients [ 3 ] and as much as 3 to 4 logs in genotype 2-infected patients [ 4 ] . Subsequently, a slower second phase of HCV RNA decline ensues. Triphasic viral declines also have been observed in some patients [5] [6] [7] . A triphasic decline consists of a fi rst phase (1-2 days) with rapid virus load decline followed by a shoulder phase (4-28 days), during which virus load decays slowly or remains constant, and a third phase of renewed viral decay. In nonresponders, there may be no viral decline (null response) or a fi rst phase followed by no second-phase decline (fl at partial response) or rebound to baseline level. Figure 1 shows typical examples of these viral load profi les under therapy.
HCV RNA kinetics during and after liver transplantation
Detailed studies of HCV RNA kinetics during the anhepatic phase and immediately after liver transplantation were recently reported [ 8-10 , 11•• ] . Most patients showed a rapid viral decline during the anhepatic phase, followed by a similar decline several hours after graft reperfusion. Thereafter, some patients reached undetectable viral levels and then had a viral rebound, or had a viral rebound immediately following the rapid decline. Others had a biphasic decline before the viral rebound, with either a viral plateau or a slower decline. After approximately 4 to 55 days post transplantation, viral concentrations exceeded pretransplantation levels.
Models of HCV RNA Kinetics
A new fi eld called viral dynamics emerged in 1995, with an initial goal of modeling HIV infection and treatment [ 12 , 13 ] . This approach was adapted in 1998 by Neumann et al. [ 3 ] to study the kinetics of the HCV RNA response to high-dose daily IFN. Since then, much progress has been made in our understanding of HCV RNA dynamics during primary infection [ 14 ] , under treatment, and during (and after) liver transplantation [ 9 , 10 ] . Kinetic models have taken into consideration the different pharmacokinetics of standard and pegylated forms of IFN [ 15 , 16•• ] and have incorporated alanine aminotransferase (ALT) kinetics [ 17 , 18 ] and aspects of host responses to provide a more comprehensive picture of the biology underlying changes in HCV RNA levels during therapy. Models and their use in clinical practice are explained in the following sections and summarized in Table 1 and Table 2 .
Model of HCV RNA infection and treatment
A model of HCV infection and treatment introduced by Neumann et al.
[ 3 ] has proved extremely useful in analyzing HCV RNA decay under drug therapy.
Cells that are susceptible to HCV infection are termed target cells, T . The model assumes that target cells are produced at a constant rate s , and die at rate d T per cell. Upon interaction with HCV, these cells become productively infected cells, I , with infection rate constant β . Infected cells produce viral particles (virions), V , at rate p per infected cell and are lost at a rate δ per infected cell. Virions are cleared at a constant rate c . Therapy is assumed to act by partially blocking virion production, with effectiveness ε , and by reducing the rate of infection, with effectiveness η , where ε and η vary between 0 and 1, with 1 meaning 100% effectiveness.
First-phase HCV RNA decline during interferon-α -based therapy
Our initial studies showed that there was a dose-dependent reduction in HCV RNA levels over the fi rst 24 to 48 hours, followed by a slower second-phase decline in patients who were given different dosages of IFN-α -2b [ 3 , 19 ] . To explain this, Neumann et al. [ 3 ] predicted that IFN must interfere with the ability of infected cells to produce or release virus, and this has recently been confi rmed in various cell-culture systems [ 20 ] . In addition, Neumann et al. [ 3 ] suggested that if one examines only the fi rst phase and assumes that on this time scale the target and infected cell numbers remain close to their levels before therapy, then model (1) predicts that viral load will decline from its baseline value, V 0 , according to the equation. Viral decay occurs after time t 0 , which corresponds to the pharmacologic delay (7-10 hours) [ 3 ] . Neumann et al.
[ 3 ] fi tted this equation to the experimental data collected over the fi rst 2 days of treatment in each patient, and the parameters c and ε were estimated. The mean intrinsic clearance rate was c = 6.2 ± 1.8 day -1 , giving a viral halflife (ie, the time it takes for half the virus to be cleared from circulation) of 2.7 hours (range, 1.5-4.6 hours). IFN effectiveness demonstrated strong dose dependency, with an average drug effectiveness of ε = 81% under a 5-mIU IFN dose and ε approximately 95% under 10-mIU and 15-mIU doses. Equation (2) predicts that the viral load will decline to the value (1 -ε ) V 0 at times longer than 1/ c , the average free virion lifetime in serum. Thus, the effectiveness in blocking virion production or release is 
